search
Back to results

The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects

Primary Purpose

Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
The SHINE SYSTEM
Sponsored by
Indigo Diabetes NV
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Diabetes Mellitus focused on measuring Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ketoacidosis, Hyperglycemia, Hypoglycemia, GCM

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects willing to sign an informed consent form (ICF)
  • Adult subjects, age ≥ 18
  • Subjects willing to comply to study protocol requirements (study visits with frequent venous blood sampling and deliberate insulin, glucose, ketone and lactate (sub study only) challenges)
  • Subjects willing to wear a Dexcom G6 CGM during duration of the study
  • Subjects willing to charge the FUSHO SENSOR/ED and CHARGER on daily basis
  • Patients with type 1 diabetes mellitus (T1DM) according to WHO criteria, diagnosed for at least 12 months prior to screening, on Multiple Daily Injections (MDI), not on insulin pump treatment during the course of the study
  • Patients with type 2 diabetes mellitus (T2DM) on Intensive Insulin Therapy (IIT), with a minimum of four injections per day and known dosing parameters

Exclusion Criteria:

  • Known allergy to PDMS
  • Subjects with a contraindication to undergo challenging tests (i.e., ischemic heart disease, epilepsy, panhypopituitarism, hypoadrenalism, untreated hypothyroidism)
  • History of severe hypoglycaemia in the previous 6 months. Severe hypoglycaemia is defined as hypoglycaemia resulting in loss of consciousness or seizure
  • History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months
  • History of, hepatitis C or HIV or other disease transmissible by blood
  • A condition requiring or likely to require magnetic resonance imaging (MRI) during the study duration
  • Female subjects who are pregnant, planning on becoming pregnant or nursing
  • Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor are allowed).
  • Anemia identified by a haemoglobin <14 g/dL for men or <12 g/dL for women
  • The presence of any other active implanted device
  • The presence of any other CGM sensor or transmitter located in lower abdomen or back (other location is acceptable)
  • Waist circumference of >120 cm
  • Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Sites / Locations

  • University Hospital ÀntwerpRecruiting
  • Lapeyronie Montpellier University Hospital
  • University Medical Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

The SHINE SYSTEM

Arm Description

Outcomes

Primary Outcome Measures

Primary Safety Objectives: Confirm safe implantation of the SENSOR in human subcutaneous tissue (insertion procedural safety)
Incidence of FUSHO SENSOR insertion procedure-related serious adverse events within 30 days from implant
Primary Safety Objectives: Confirm the safety of the device during the implantation period (safety of device integration in the subcutaneous tissue)
Assessment of device related adverse events during 6 months of implant use
Primary Initial Performance Objectives: Demonstration of SENSOR stability
Demonstrate that device is able to provide a stable spectral signal and whether it is feasible to use these data points to create an algorithm. SENSOR Stability is defined by maintaining its spectral characteristics (availability, intensity and range) over its implantation duration of 6 months
Primary Initial Performance Objectives: Confirm the ability to (a) retrieve spectral and metadata from the SENSOR and upload to the CLOUD
(a) Evaluation of the Bluetooth transmission: successful transmission of the spectral data from FUSHO SENSOR to the CLOUD via Bluetooth Low Energy (BLE). The proportion of data transmitted to the CLOUD versus the expected amount of data when device used as intended
Primary Initial Performance Objectives: Confirm the ability to (b) show the battery and SENSOR-ED connectivity status to subject
(b) Display of battery and FUSHO SENSOR-ED connectivity status to subject
Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.
(c) Charging (charging efficiency) of the FUSHO SENSOR, as recorded on the APP

Secondary Outcome Measures

Secondary Safety Objectives: Confirm safe explantation of the SENSOR from human subcutaneous tissue (removal procedural safety)
Incidence of FUSHO SENSOR removal-related serious adverse events within 30 days from explant
Secondary Safety Objectives: Confirm general safety in the clinic and during home use (general safety)
All Serious Adverse Events collected throughout the study and reported at 30 days, 3 months and 6 months Assessment of device related adverse events at 30 days, 3 and 6 months Wound status at each visit. Final result on healing just at explant.
Secondary Performance Objective: Assessment of procedural success for the implantation procedure
Successful FUSHO implantation (first implant in case of re-implant) procedure on average performed within 20 minutes (from incision to closure) without occurrence of procedure related SAEs
Secondary Performance Objective: Assessment of procedural success for the explantation procedure
Successful FUSHO explantation procedure on average performed within 20 minutes (from incision to closure) without occurrence of procedure related SAEs
Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure
Procedural success defined as implantation of the FUSHO SENSOR within an average of 20 minutes (from start incision to closing of skin) without the occurrence of procedure related adverse events up to 30 days after implant
Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure
The primary initial performance endpoint at further timepoints through 30 days and 3 months

Full Information

First Posted
September 19, 2022
Last Updated
October 24, 2022
Sponsor
Indigo Diabetes NV
search

1. Study Identification

Unique Protocol Identification Number
NCT05597605
Brief Title
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
Official Title
The SHINE Study: An Open Label, Interventional, Multicentre, Prospective Feasibility Study, Designed to Evaluate the Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 21, 2022 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Indigo Diabetes NV

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objectives of SHINE study are to confirm the safety aspects of the SHINE SYSTEM. Moreover, the goal of this clinical investigation is the initial evaluation of sensor's performance by assessing sensor's ability to qualitatively detect the appropriate analytes in subjects with diabetes of 18 years and older.
Detailed Description
Indigo Diabetes N.V. is currently developing an active implantable medical device, intended to be used for real time, continuous measurement of glucose and ketone levels in the interstitial fluid in adults (18 years and older) with diabetes mellitus. Based on the outcome of the GLOW Study, Indigo developed a prototype, the SHINE SYSTEM, that will be used during the planned clinical investigation (SHINE study).The objectives of SHINE study are to confirm the safety aspects of the SHINE system. Moreover, the goal of this clinical investigation is the initial evaluation of sensor's performance by assessing sensor's ability to qualitatively detect the appropriate analytes in subjects with diabetes of 18 years and older. Clinical performance of the device will not be formally evaluated during this clinical investigation. The study is designed to enable data collection (i.e., continuous collection of data by FUSHO sensor, implanted in study subject, combined with simultaneous collection of data collected by Dexcom G6), which will be used to develop the software algorithm in a future version of the device, in order to display measurements in real-time to the user.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ketoacidosis, Diabetic, Hyperglycaemia (Diabetic), Hypoglycemia
Keywords
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Ketoacidosis, Hyperglycemia, Hypoglycemia, GCM

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The SHINE SYSTEM
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
The SHINE SYSTEM
Intervention Description
The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
Primary Outcome Measure Information:
Title
Primary Safety Objectives: Confirm safe implantation of the SENSOR in human subcutaneous tissue (insertion procedural safety)
Description
Incidence of FUSHO SENSOR insertion procedure-related serious adverse events within 30 days from implant
Time Frame
30 days
Title
Primary Safety Objectives: Confirm the safety of the device during the implantation period (safety of device integration in the subcutaneous tissue)
Description
Assessment of device related adverse events during 6 months of implant use
Time Frame
6 months
Title
Primary Initial Performance Objectives: Demonstration of SENSOR stability
Description
Demonstrate that device is able to provide a stable spectral signal and whether it is feasible to use these data points to create an algorithm. SENSOR Stability is defined by maintaining its spectral characteristics (availability, intensity and range) over its implantation duration of 6 months
Time Frame
6 months
Title
Primary Initial Performance Objectives: Confirm the ability to (a) retrieve spectral and metadata from the SENSOR and upload to the CLOUD
Description
(a) Evaluation of the Bluetooth transmission: successful transmission of the spectral data from FUSHO SENSOR to the CLOUD via Bluetooth Low Energy (BLE). The proportion of data transmitted to the CLOUD versus the expected amount of data when device used as intended
Time Frame
6 months
Title
Primary Initial Performance Objectives: Confirm the ability to (b) show the battery and SENSOR-ED connectivity status to subject
Description
(b) Display of battery and FUSHO SENSOR-ED connectivity status to subject
Time Frame
6 months
Title
Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.
Description
(c) Charging (charging efficiency) of the FUSHO SENSOR, as recorded on the APP
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Secondary Safety Objectives: Confirm safe explantation of the SENSOR from human subcutaneous tissue (removal procedural safety)
Description
Incidence of FUSHO SENSOR removal-related serious adverse events within 30 days from explant
Time Frame
30 days
Title
Secondary Safety Objectives: Confirm general safety in the clinic and during home use (general safety)
Description
All Serious Adverse Events collected throughout the study and reported at 30 days, 3 months and 6 months Assessment of device related adverse events at 30 days, 3 and 6 months Wound status at each visit. Final result on healing just at explant.
Time Frame
6 months
Title
Secondary Performance Objective: Assessment of procedural success for the implantation procedure
Description
Successful FUSHO implantation (first implant in case of re-implant) procedure on average performed within 20 minutes (from incision to closure) without occurrence of procedure related SAEs
Time Frame
30 days
Title
Secondary Performance Objective: Assessment of procedural success for the explantation procedure
Description
Successful FUSHO explantation procedure on average performed within 20 minutes (from incision to closure) without occurrence of procedure related SAEs
Time Frame
30 days
Title
Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure
Description
Procedural success defined as implantation of the FUSHO SENSOR within an average of 20 minutes (from start incision to closing of skin) without the occurrence of procedure related adverse events up to 30 days after implant
Time Frame
30 days
Title
Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure
Description
The primary initial performance endpoint at further timepoints through 30 days and 3 months
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
Exploratory Analysis: Establishment of a model for evaluation of blood glucose, ketone and lactate values by the SENSOR by using the values obtained by other than SENSOR data
Description
Development and refinement of a model that allows correct analysis of the spectral data read and translation into glucose, ketone and lactate (for sub-study only) values. The values will be analysed in conjunction with values obtained by comperative methods and used to further adjust this model. The model is expected to be able to demonstrate increased performance by subsequent iterations based on known absolute values. Iterations are expected to be performed until values are suitable for validation
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for glucose demonstrated by Mean Absolute Relative Difference (MARD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Relative Difference (MARD) intended for evaluation of the appropriateness of the algorithm/model for prediction of glucose. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for ketones demonstrated by Mean Absolute Relative Difference (MARD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Relative Difference (MARD) intended for evaluation of the appropriateness of the algorithm/model for prediction of ketones. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for lactate demonstrated by Mean Absolute Relative Difference (MARD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Relative Difference (MARD) intended for evaluation of the appropriateness of the algorithm/model for prediction of lactate. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for glucose demonstrated by Mean Absolute Deviation (MAD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Deviation (MAD) intended for evaluation of the appropriateness of the algorithm/model for prediction of glucose. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for ketones demonstrated by Mean Absolute Deviation (MAD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Deviation (MAD) intended for evaluation of the appropriateness of the algorithm/model for prediction of ketones. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for lactate demonstrated by Mean Absolute Deviation (MAD)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Mean Absolute Deviation (MAD) intended for evaluation of the appropriateness of the algorithm/model for prediction of lactate. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for glucose demonstrated by Error Grid Analysis (EGA)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Error Grid Analysis (EGA) intended for evaluation of the appropriateness of the algorithm/model for prediction of glucose. No health outcomes (e.g. ability to predict glycaemic values) are evaluated.
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for ketones demonstrated by Error Grid Analysis (EGA)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Error Grid Analysis (EGA) intended for evaluation of the appropriateness of the algorithm/model for prediction of ketones. No health outcomes (e.g. ability to predict glycaemic values) are evaluated
Time Frame
6 months
Title
Exploratory Analysis: Accuracy of measurements for lactate demonstrated by Error Grid Analysis (EGA)
Description
Post hoc analysis of accuracy of measurements for glucose demonstrated by Error Grid Analysis (EGA) intended for evaluation of the appropriateness of the algorithm/model for prediction of lactate. No health outcomes (e.g. ability to predict glycaemic values) are evaluated
Time Frame
6 months
Title
Exploratory Analysis: Histopathology analysis of the biopsy
Description
Histopathology analysis of the biopsy at explant on macroscopic and microscopic level, with Haematoxylin-Eosin (HE) staining, to assess potential changes of surrounding cells and tissue around the sensor and local tissue tolerance/interaction by investigating local tissue inflammation (fibrosis, foreign body reaction (e.g. presence of giant cells, macrophages and other))
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects willing to sign an informed consent form (ICF) Adult subjects, age ≥ 18 Subjects willing to comply to study protocol requirements (study visits with frequent venous blood sampling and deliberate insulin, glucose, ketone and lactate (sub study only) challenges) Subjects willing to wear a Dexcom G6 CGM during duration of the study Subjects willing to charge the FUSHO SENSOR/ED and CHARGER on daily basis Patients with type 1 diabetes mellitus (T1DM) according to WHO criteria, diagnosed for at least 12 months prior to screening, on Multiple Daily Injections (MDI), not on insulin pump treatment during the course of the study Patients with type 2 diabetes mellitus (T2DM) on Intensive Insulin Therapy (IIT), with a minimum of four injections per day and known dosing parameters Exclusion Criteria: Known allergy to PDMS Subjects with a contraindication to undergo challenging tests (i.e., ischemic heart disease, epilepsy, panhypopituitarism, hypoadrenalism, untreated hypothyroidism) History of severe hypoglycaemia in the previous 6 months. Severe hypoglycaemia is defined as hypoglycaemia resulting in loss of consciousness or seizure History of diabetic ketoacidosis requiring emergency room visit or hospitalization in the previous 6 months History of, hepatitis C or HIV or other disease transmissible by blood A condition requiring or likely to require magnetic resonance imaging (MRI) during the study duration Female subjects who are pregnant, planning on becoming pregnant or nursing Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor are allowed). Anemia identified by a haemoglobin <14 g/dL for men or <12 g/dL for women The presence of any other active implanted device The presence of any other CGM sensor or transmitter located in lower abdomen or back (other location is acceptable) Waist circumference of >120 cm Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gijs Klarenbeek, MD
Phone
479 98 64 58
Ext
+32
Email
gijs.klarenbeek@indigomed.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christophe De Block, Prof. Dr.
Organizational Affiliation
University Hospital, Antwerp
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Àntwerp
City
Antwerp
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rie Braspenning, MsC
Phone
+32(0)38213000
Email
rie.braspenning@uza.be
First Name & Middle Initial & Last Name & Degree
Christophe De Block, Prof. Dr.
Facility Name
Lapeyronie Montpellier University Hospital
City
Montpellier
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Renard, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Eric Renard, Prof. Dr.
Facility Name
University Medical Centre
City
Ljubljana
Country
Slovenia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tadej Battelino, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Tadej Battelino, Prof. Dr.

12. IPD Sharing Statement

Learn more about this trial

The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects

We'll reach out to this number within 24 hrs